Matinas BioPharma Holdings Inc
AMEX:MTNB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Matinas BioPharma Holdings Inc
AMEX:MTNB
|
US |
|
Italmobiliare SpA
MIL:ITM
|
IT |
|
Hexagon AB
STO:HEXA B
|
SE |
|
Cosco Shipping International (Singapore) Co Ltd
SGX:F83
|
SG |
|
V
|
Vinyl Group Ltd
ASX:VNL
|
AU |
|
Tasman Resources Ltd
ASX:TAS
|
AU |
|
High Co SA
PAR:HCO
|
FR |
|
Ambika Cotton Mills Ltd
NSE:AMBIKCO
|
IN |
|
B
|
Bathurst Resources Ltd
OTC:BTURF
|
NZ |
|
Cash Converters International Ltd
ASX:CCV
|
AU |
|
Shun Wo Group Holdings Ltd
HKEX:1591
|
HK |
|
PharmaSGP Holding SE
XETRA:PSG
|
DE |
|
Triveni Turbine Ltd
NSE:TRITURBINE
|
IN |
|
Alignvest Acquisition II Corp
TSX:SFC
|
CA |
|
Bausch Health Companies Inc
TSX:BHC
|
CA |
|
Mas Murni Indonesia Tbk PT
IDX:MAMI
|
ID |
|
P
|
Para Light Electronics Co Ltd
TWSE:6226
|
TW |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
US |
|
Appian Corp
NASDAQ:APPN
|
US |
|
OEM International AB
STO:OEM B
|
SE |
|
T
|
TAJ GVK Hotels and Resorts Ltd
NSE:TAJGVK
|
IN |
Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 34 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform) to maximize global clinical impact and patient access. The Company’s lead anti-fungal product candidate, MAT2203, is an application of its LNC Platform to a broad spectrum and potent anti-fungal drug called amphotericin B. Its second clinical-stage LNC-based product candidate is MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including NTM, as well as various multidrug-resistant gram-negative and intracellular bacterial infections. The company also has internal discovery programs ongoing in the formulation and delivery of small oligonucleotides, namely antisense oligonucleotides (ASOs) and silencing or short interfering RNAs (siRNAs).
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 34 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform) to maximize global clinical impact and patient access. The Company’s lead anti-fungal product candidate, MAT2203, is an application of its LNC Platform to a broad spectrum and potent anti-fungal drug called amphotericin B. Its second clinical-stage LNC-based product candidate is MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including NTM, as well as various multidrug-resistant gram-negative and intracellular bacterial infections. The company also has internal discovery programs ongoing in the formulation and delivery of small oligonucleotides, namely antisense oligonucleotides (ASOs) and silencing or short interfering RNAs (siRNAs).
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
